Artemis Therapeutics Inc

OTC: MNKA    
Share price (5/9/24): $0.03    
Market cap (5/9/24): $3.361 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.9
from S-1/A 6 pages The Parties Therefore Agree, Declare and Stipulate as Follows
12/34/56
EX-10.8
from S-1/A 9 pages Form of Indemnification Agreement
12/34/56
EX-10.8
from S-1 9 pages Form of Indemnification Agreement
12/34/56
EX-10.1
from 8-K 4 pages Services Agreement
12/34/56
EX-10.7
from 8-K 3 pages Debt Forgiveness Agreement
12/34/56
EX-10.6
from 8-K 4 pages Re: Warrant Exchange Agreement
12/34/56
EX-10.5
from 8-K 2 pages Preliminary Certificate for the Import of Sensitive Food According to Section 64 to the Law* Preliminary Certificate for Import: 541618 Date of Origin: February 28, 2022 Date of Issue: February 28, 2022 This Certificate Is Valid Until February 28, 2023
12/34/56
EX-10.4
from 8-K 8 pages Agreement Which Was Drawn Up and Signed on December 14, 2021
12/34/56
EX-10.3
from 8-K 5 pages Agreement
12/34/56
EX-10.2
from 8-K 4 pages First Amendment to Share Exchange Agreement
12/34/56
EX-10.1
from 10-Q 33 pages Share Exchange Agreement
12/34/56
EX-10.2
from 10-Q 6 pages Artemis Therapeutics Inc. Unsecured Promissory Note
12/34/56
EX-10.1
from 10-Q 6 pages Artemis Therapeutics Inc. Unsecured Promissory Note
12/34/56
EX-10.1
from 10-Q 6 pages Artemis Therapeutics Inc. Unsecured Promissory Note
12/34/56
EX-10.1
from 8-K 2 pages First Amendment to Employment Agreement
12/34/56
EX-10.1
from 8-K 36 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 16 pages Employment Agreement
12/34/56
EX-10.1
from 8-K/A 59 pages **Confidential Portions Have Been Omitted Pursuant to a Request for Confidential Treatment and Have Been Filed Separately With the Securities and Exchange Commission (The “Commission”)** License Agreement
12/34/56
EX-10.1
from 8-K 13 pages Employment Agreement
12/34/56
EX-10.1
from 8-K/A 59 pages **Confidential Portions Have Been Omitted Pursuant to a Request for Confidential Treatment and Have Been Filed Separately With the Securities and Exchange Commission (The “Commission”)** License Agreement
12/34/56